Dr. Sabine Chlosta joined Triumvira in January 2018. Prior to Triumvira, Dr. Chlosta consulted for Aurora BioPharma, a start-up company developing CAR-T cells in solid tumors, and was previously a Senior Medical Director at Merck/MSD where she played a key role in the development of their PD-1 inhibitor Keytruda® in non-Hodgkin lymphoma and also oversaw trials in other indications. Earlier in her career, Dr. Chlosta was a medical director at Glycomimetics where she helped launch the company’s first trial in hematology/oncology. Dr. Chlosta started her career in industry as a Fellow in oncology drug development at Novartis overseeing clinical pharmacology trials with a small molecule and helped the team launch the CAR-T lymphoma program with CTL019, Kymriah®.
Dr. Chlosta is board-certified in pediatric hematology-oncology and in pediatrics. She completed post-graduate training in hematology-oncology at the combined program of Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College and in pediatrics at State University of New York at Downstate. Prior to entering clinical training in the United States, Dr. Chlosta was a visiting research Fellow in immunology at Harvard. Dr. Chlosta received her PhD degree in Immunology and Infectious Diseases and her MD degree from Charité Medical School / Free University.
